Osteoarthritis Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Th

Osteoarthritis Pipeline constitutes 100+ key companies continuously working towards developing 110+ Osteoarthritis treatment therapies, analyzes DelveInsight.

Osteoarthritis Overview:

Osteoarthritis (OA) is the most prevalent type of arthritis, often referred to as "wear and tear" arthritis or degenerative joint disease. It most commonly affects the knees, hips, and hands. In OA, the protective cartilage cushioning the ends of bones in the joints gradually deteriorates, and the underlying bone may begin to change. These changes typically develop slowly and worsen over time. OA leads to symptoms such as joint pain, stiffness, and swelling, and in more advanced cases, it can significantly reduce mobility and interfere with daily activities. Common signs include pain that intensifies with use and eases with rest, brief stiffness after periods of inactivity (usually less than 30 minutes), a feeling of joint instability, and sometimes a grinding or creaking sensation during movement. Swelling may also occur, especially after extended joint use.

Download our report @ https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Osteoarthritis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Osteoarthritis Therapeutics Market.

Key Takeaways from the Osteoarthritis Pipeline Report

DelveInsight's Osteoarthritis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Osteoarthritis treatment.
In March 2025, Doron Therapeutics received RMAT designation for MOTYS, a biologic drug aimed at treating knee osteoarthritis. This designation is expected to expedite the development and review process, potentially bringing the therapy to patients more quickly.
In December 2024, Genascence Corporation's GNSC-001, a gene therapy for knee osteoarthritis, also received Fast Track designation, highlighting its promise in offering long-term relief for musculoskeletal diseases.
In October 2024, the FDA granted Fast Track designation to Sun Pharma's MM-II, recognizing its potential to address unmet medical needs in osteoarthritis treatment.
Key Osteoarthritis companies such as ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others are evaluating new drugs for Osteoarthritis to improve the treatment landscape.
Promising Osteoarthritis pipeline therapies in various stages of development include Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others.

Osteoarthritis Pipeline Analysis
The Osteoarthritis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Osteoarthritis Market.

Categorizes Osteoarthritis therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Osteoarthritis drugs under development based on:

Stage of development

Osteoarthritis Route of administration

Target receptor

Monotherapy vs. combination therapy

Osteoarthritis Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Osteoarthritis Licensing agreements

Funding and investment activities supporting future Osteoarthritis market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Osteoarthritis Emerging Drugs

Lorecivivint: Biosplice Therapeutics
EP-104IAR: Eupraxia Pharmaceuticals
DFV890: Novartis
4P004: 4P-Pharma
GNSC 001: Genascence

Osteoarthritis Companies

There are over 100 prominent companies actively engaged in developing treatments for Osteoarthritis. Among them, Biosplice Therapeutics has a drug candidate that is currently in the most advanced stage of development-Phase III.

DelveInsight's report covers around 110+ products under different phases of Osteoarthritis clinical trials like

Osteoarthritis Late stage Therapies (Phase III)
Osteoarthritis Mid-stage Therapies (Phase II)
Osteoarthritis Early-stage Therapies (Phase I)
Osteoarthritis Pre-clinical and Osteoarthritis Discovery stage Therapies
Osteoarthritis Discontinued & Inactive Therapies

Osteoarthritis pipeline report provides the Osteoarthritis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Osteoarthritis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Osteoarthritis Therapies and Key Osteoarthritis Companies: Osteoarthritis Clinical Trials and recent advancements https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Osteoarthritis Pipeline Therapeutic Assessment
• Osteoarthritis Assessment by Product Type
• Osteoarthritis By Stage
• Osteoarthritis Assessment by Route of Administration
• Osteoarthritis Assessment by Molecule Type

Download Osteoarthritis Sample report to know in detail about the Osteoarthritis treatment market @ Osteoarthritis Therapeutic Assessment https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Osteoarthritis Current Treatment Patterns
4. Osteoarthritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Osteoarthritis Late-Stage Products (Phase-III)
7. Osteoarthritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Osteoarthritis Discontinued Products
13. Osteoarthritis Product Profiles
14. Osteoarthritis Key Companies
15. Osteoarthritis Key Products
16. Dormant and Discontinued Products
17. Osteoarthritis Unmet Needs
18. Osteoarthritis Future Perspectives
19. Osteoarthritis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Osteoarthritis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.